Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
10.1165/rcmb.2006-0478OC 26 MaugA
Apelin-VEGF-C mRNA delivery as therapeutic for the treatment of secondary lymphedema
Reduced mobility due to fatigue or physical disability may limit exercise capacity, whilst some disease-modifying therapies and symptomatic treatments (particularly corticosteroids used during relapses) can contribute to weight gain
Non-genotype-specific role of the hepatitis C virus 5 untranslated region in virus production and in inhibition by interferon
(17(8)):e01712 doi:10.1213/XAA.0000000000001712
For patients with baseline NAFLD (non-alcoholic fatty liver disease) or elevated transaminases, glutathione supplementation timed correctly can support hepatic antioxidant capacity during this metabolic surge
US$ 25.49
US$ 23.89
US$ 22.80
